169 related articles for article (PubMed ID: 26721633)
1. Decreased Wnt5a Expression is a Poor Prognostic Factor in Triple-Negative Breast Cancer.
Zhong Z; Shan M; Wang J; Liu T; Shi Q; Pang D
Med Sci Monit; 2016 Jan; 22():1-7. PubMed ID: 26721633
[TBL] [Abstract][Full Text] [Related]
2. Elevated expression of HABP1 is a novel prognostic indicator in triple-negative breast cancers.
Wang J; Song Y; Liu T; Shi Q; Zhong Z; Wei W; Huang S; Pang D
Tumour Biol; 2015 Jun; 36(6):4793-9. PubMed ID: 25794640
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of Ki-67 proliferating index in triple negative breast carcinomas.
Mrklić I; Ćapkun V; Pogorelić Z; Tomić S
Pathol Res Pract; 2013 May; 209(5):296-301. PubMed ID: 23601837
[TBL] [Abstract][Full Text] [Related]
4. FOXO3a expression is associated with lymph node metastasis and poor disease-free survival in triple-negative breast cancer.
Rehman A; Kim Y; Kim H; Sim J; Ahn H; Chung MS; Shin SJ; Jang K
J Clin Pathol; 2018 Sep; 71(9):806-813. PubMed ID: 29588373
[TBL] [Abstract][Full Text] [Related]
5. A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status.
Shen S; Sun Q; Liang Z; Cui X; Ren X; Chen H; Zhang X; Zhou Y
PLoS One; 2014; 9(6):e100664. PubMed ID: 24945253
[TBL] [Abstract][Full Text] [Related]
6. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer.
Ma F; Ding X; Fan Y; Ying J; Zheng S; Lu N; Xu B
PLoS One; 2014; 9(11):e112765. PubMed ID: 25393310
[TBL] [Abstract][Full Text] [Related]
7. Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients.
Ricciardi GR; Adamo B; Ieni A; Licata L; Cardia R; Ferraro G; Franchina T; Tuccari G; Adamo V
PLoS One; 2015; 10(6):e0128368. PubMed ID: 26039245
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients.
Urru SAM; Gallus S; Bosetti C; Moi T; Medda R; Sollai E; Murgia A; Sanges F; Pira G; Manca A; Palmas D; Floris M; Asunis AM; Atzori F; Carru C; D'Incalci M; Ghiani M; Marras V; Onnis D; Santona MC; Sarobba G; Valle E; Canu L; Cossu S; Bulfone A; Rocca PC; De Miglio MR; Orrù S
BMC Cancer; 2018 Jan; 18(1):56. PubMed ID: 29310602
[TBL] [Abstract][Full Text] [Related]
9. FOXC1-induced non-canonical WNT5A-MMP7 signaling regulates invasiveness in triple-negative breast cancer.
Han B; Zhou B; Qu Y; Gao B; Xu Y; Chung S; Tanaka H; Yang W; Giuliano AE; Cui X
Oncogene; 2018 Mar; 37(10):1399-1408. PubMed ID: 29249801
[TBL] [Abstract][Full Text] [Related]
10. Expression and prognostic significance of ECT2 in invasive breast cancer.
Wang HK; Liang JF; Zheng HX; Xiao H
J Clin Pathol; 2018 May; 71(5):442-445. PubMed ID: 29051317
[TBL] [Abstract][Full Text] [Related]
11. Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression.
Reyes ME; Fujii T; Branstetter D; Krishnamurthy S; Masuda H; Wang X; Reuben JM; Woodward WA; Edwards BJ; Hortobagyi GN; Tripathy D; Dougall WC; Eckhardt BL; Ueno NT
Breast Cancer Res Treat; 2017 Jul; 164(1):57-67. PubMed ID: 28417335
[TBL] [Abstract][Full Text] [Related]
12. Low Expression of Circulating MicroRNA-34c is Associated with Poor Prognosis in Triple-Negative Breast Cancer.
Zeng Z; Chen X; Zhu D; Luo Z; Yang M
Yonsei Med J; 2017 Jul; 58(4):697-702. PubMed ID: 28540980
[TBL] [Abstract][Full Text] [Related]
13. Expression of hepatic Wnt5a and its clinicopathological features in patients with hepatocellular carcinoma.
Wang L; Yao M; Fang M; Zheng WJ; Dong ZZ; Pan LH; Zhang HJ; Yao DF
Hepatobiliary Pancreat Dis Int; 2018 Jun; 17(3):227-232. PubMed ID: 29709351
[TBL] [Abstract][Full Text] [Related]
14. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.
Jin MS; Hyun CL; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Ryu HS
Tumour Biol; 2016 Apr; 37(4):4743-53. PubMed ID: 26515337
[TBL] [Abstract][Full Text] [Related]
15. MiR-128 regulation of glucose metabolism and cell proliferation in triple-negative breast cancer.
Xiao M; Lou C; Xiao H; Yang Y; Cai X; Li C; Jia S; Huang Y
Br J Surg; 2018 Jan; 105(1):75-85. PubMed ID: 29116653
[TBL] [Abstract][Full Text] [Related]
16. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
[TBL] [Abstract][Full Text] [Related]
17. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
de Nonneville A; Gonçalves A; Zemmour C; Cohen M; Classe JM; Reyal F; Colombo PE; Jouve E; Giard S; Barranger E; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
Eur J Cancer; 2017 Oct; 84():34-43. PubMed ID: 28780480
[TBL] [Abstract][Full Text] [Related]
19. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.
Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X
Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701
[TBL] [Abstract][Full Text] [Related]
20. TTK is a favorable prognostic biomarker for triple-negative breast cancer survival.
Xu Q; Xu Y; Pan B; Wu L; Ren X; Zhou Y; Mao F; Lin Y; Guan J; Shen S; Zhang X; Wang C; Zhong Y; Zhou L; Liang Z; Zhao H; Sun Q
Oncotarget; 2016 Dec; 7(49):81815-81829. PubMed ID: 27833085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
